Biotechnology company Alligator Bioscience AB (STO:ATORX) on Wednesday announced the publication of clinical data for its 4-1BB agonist, ATOR-1017, in the Journal for ImmunoTherapy of Cancer.

The data, from a first-in-human trial, demonstrates encouraging safety and tolerability in patients with advanced cancer.

The publication also highlights early signs of clinical efficacy, and pharmacokinetic and pharmacodynamic analyses demonstrate proof of mechanism. These findings support the therapeutic potential of ATOR-1017, particularly in combination with other cancer therapies.

Alligator continues to prioritise the development of its lead candidate, mitazalimab, while exploring strategic options for advancing ATOR-1017.